Onconetix, Inc. Equity Classified Written Call Option Modification Equity Issuance Increase Decrease In Equity Amount
Onconetix, Inc. (ONCO) reported Equity Classified Written Call Option Modification Equity Issuance Increase Decrease In Equity Amount of $2.60 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Shareholders' Equity
us-gaap:EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount · last filed 2023-11-17
- 2023-09-30: Equity Classified Written Call Option Modification Equity Issuance Increase Decrease In Equity Amount 9 month $2.60M.
| Period end | Equity Classified Written Call Option Modification Equity Issuance Increase Decrease In Equity Amount 9 month |
|---|---|
| 2023-09-30 | $2.60M 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |